PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aziyo Biologics, Inc. (AZYO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS05479K1060
CUSIP05479K106
SectorHealthcare
IndustryMedical Devices

Highlights

Market Cap$24.21M
EPS-$2.18
Revenue (TTM)$48.40M
Gross Profit (TTM)$19.22M
EBITDA (TTM)-$20.42M
Year Range$1.10 - $2.80
Target Price$10.50
Short %1.50%
Short Ratio3.98

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Aziyo Biologics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Aziyo Biologics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%Fri 20Oct 22Tue 24Thu 26Sat 28Mon 30NovemberFri 03Nov 05Tue 07
24.29%
2.45%
AZYO (Aziyo Biologics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period


PeriodReturnBenchmark
Year-To-DateN/A5.06%
1 monthN/A-3.23%
6 monthsN/A17.14%
1 yearN/A20.62%
5 years (annualized)N/A11.54%
10 years (annualized)N/A10.37%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-4.67%-18.18%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Aziyo Biologics, Inc. (AZYO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AZYO
Sharpe ratio
No data
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.76, compared to the broader market-2.00-1.000.001.002.003.001.76
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.57, compared to the broader market-4.00-2.000.002.004.002.57
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.31
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.001.002.003.004.005.001.33
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.04, compared to the broader market0.0010.0020.0030.007.04

Sharpe Ratio


Rolling 12-month Sharpe Ratio-0.500.000.501.00Fri 20Oct 22Tue 24Thu 26Sat 28Mon 30NovemberFri 03Nov 05Tue 07
-0.68
0.99
AZYO (Aziyo Biologics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aziyo Biologics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Fri 20Oct 22Tue 24Thu 26Sat 28Mon 30NovemberFri 03Nov 05Tue 07
-90.01%
-8.63%
AZYO (Aziyo Biologics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aziyo Biologics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aziyo Biologics, Inc. was 93.11%, occurring on Sep 13, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-93.11%Feb 4, 2021656Sep 13, 2023
-25.72%Oct 9, 202021Nov 6, 202018Dec 3, 202039
-16.6%Dec 4, 20209Dec 16, 202019Jan 14, 202128
-7.75%Jan 15, 20212Jan 19, 20211Jan 20, 20213
-5.22%Jan 21, 20211Jan 21, 20212Jan 25, 20213

Volatility

Volatility Chart

The current Aziyo Biologics, Inc. volatility is 23.64%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%20.00%Fri 20Oct 22Tue 24Thu 26Sat 28Mon 30NovemberFri 03Nov 05Tue 07
23.64%
4.32%
AZYO (Aziyo Biologics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aziyo Biologics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items